|
|
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission File Number)
|
(IRS Employer
Identification No.)
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol
|
Name of each exchange on which registered
|
|
|
|
SECTION 8
|
— OTHER ITEMS
|
SECTION 9
|
— FINANCIAL STATEMENTS AND EXHIBITS
|
|
(d) |
Exhibits. The following
exhibit is filed with this Report:
|
Exhibit
No.
|
Description
|
|
Press release
|
Galectin Therapeutics Inc.
|
|||
Date:
|
October 12, 2022
|
By:
|
/s/ Jack W. Callicutt
|
Jack W. Callicutt
Chief Financial Officer
|